Powder: -20°C for 3 years In solvent: -80°C for 2 years
Alrizomadlin 是一种具有口服活性的 MDM2 抑制剂，IC50 为 3.8 nM，Ki 分别为 1 nM[1]。 Alrizomadlin 阻断 MDM2 和 p53 的相互作用，并以 p53 依赖性方式诱导细胞周期停滞和细胞凋亡。
| 产品描述 | Alrizomadlin is an orally active inhibitor of MDM2 with IC50 of 3.8 nM and Ki of 1 nM, respectively[1]. Alrizomadlin blocks the interaction of MDM2 and p53 and induces cell-cycle arrest and apoptosis in a p53-dependent manner. |
| 靶点活性 | APG-115:3.8 nM |
| 体外活性 | Alrizomadlin (0.001-100 μM) inhibits cell proliferation in a concentration-dependent manner(IC50s: 18.9 nM and 103.5 ± 18.3 nM respectively in AGS and MKN45 cells). Alrizomadlin (0.02-0.2 μM) activates p53 to enhance radiosensitivity in AGS and MKN45 cells and enhances the anti-proliferative effect of radiotherapy at different radiation doses. Stable knockout of p53 abrogates expression of MDM2, p53, p21, PUMA, BAX, Cleaved-caspase3, γH2AX. Alrizomadlin affects progression by inducing cells arrested at G0/G1 phase[3]. Alrizomadlin (0.3 μM-10 μM) leads to a concentration-dependent cell cycle arrest in G2/M phases and decreases S-phase in p53 wide-type cell lines (TPC-1, KTC-1)[4]. |
| 体内活性 | In male BALB/c athymic nude mice with MKN45 cells, Alrizomadlin (100 mg/kg; orally) enhances radiation antitumor effect in gastric adenocarcinoma[3]. |
| 别名 | AA-115, APG-115 |
| 分子量 | 642.59 |
| 分子式 | C34H38Cl2FN3O4 |
| CAS No. | 1818393-16-6 |
Powder: -20°C for 3 years In solvent: -80°C for 2 years
DMSO: 90mg/mL (140.1mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
参考文献
剂量换算对于不同动物的给药剂量换算，您也可以参考 更多
体内实验配液计算器计算器bottom
您可能有的问题的答案可以在抑制剂处理说明中找到，包括如何准备库存溶液，如何存储产品，以及基于细胞的分析和动物实验需要特别注意的问题。
Alrizomadlin 1818393-16-6 Apoptosis Mdm2 AA-115 APG-115 Inhibitor inhibitor inhibit
沪公网安备 31010602006700号
